These enterprise-level partnerships offer pharma the chance to build capabilities and accelerate time to market; meanwhile, they offer health tech firms marketable validation of their value, a source of funding and a commercialization partner. If not carefully managed, however, these partnerships can easily fall prey to cost and operational inefficiencies, commercialization delays and a breakdown of the working model.
Comments